Fuxin Long Rui Pharmaceutical is an API manufacturer. It holds 19 active US drug master files across a filed portfolio of 18 molecules.
| Molecule | Regulators | Docs |
|---|---|---|
| Empagliflozin | SFDA (Saudi Arabia), US FDA | 2 |
| Sitagliptin | US FDA | 2 |
| Alogliptin | US FDA | 1 |
| Bendamustine | US FDA | 1 |
| Canagliflozin | US FDA | 1 |
| Daclatasvir | US FDA | 1 |
| Dapagliflozin | US FDA | 1 |
| Entecavir | US FDA | 1 |
| Ipragliflozin | US FDA | 1 |
| Ivabradine | US FDA | 1 |
| Ledipasvir | US FDA | 1 |
| Linagliptin | US FDA | 1 |
| Omarigliptin | US FDA | 1 |
| Pitavastatin | US FDA | 1 |
| Rivaroxaban | US FDA | 1 |
| Saxagliptin | US FDA | 1 |
| Sofosbuvir | US FDA | 1 |
| Vildagliptin | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 4 | None |
Choose your molecules and target markets. Fuxin Long Rui Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free